請用此 Handle URI 來引用此文件：
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/80404完整後設資料紀錄
| DC 欄位 | 值 | 語言 |
|---|---|---|
| dc.contributor.advisor | 楊銘欽(Ming-Chin Yang) | |
| dc.contributor.author | Yi-Ting Li | en |
| dc.contributor.author | 李義亭 | zh_TW |
| dc.date.accessioned | 2022-11-24T03:05:55Z | - |
| dc.date.available | 2022-02-16 | |
| dc.date.available | 2022-11-24T03:05:55Z | - |
| dc.date.copyright | 2022-02-16 | |
| dc.date.issued | 2022 | |
| dc.date.submitted | 2022-01-11 | |
| dc.identifier.citation | Abrahamsen, B., van Staa, T., Ariely, R., Olson, M., Cooper, C. (2009). Excess mortality following hip fracture: a systematic epidemiological review. Osteoporos Int, 20(10), 1633-1650. doi:10.1007/s00198-009-0920-3 2. Akehurst, R., Brereton, N., Ariely, R., Lusa, T., Groot, M., Foss, P., Boonen, S. (2011). The cost effectiveness of zoledronic acid 5 mg for the management of postmenopausal osteoporosis in women with prior fractures: evidence from Finland, Norway and the Netherlands. J Med Econ, 14(1), 53-64. doi:10.3111/13696998.2010.545563 3. Banta, H. D., Thacker, S. B. (1990). The case for reassessment of health care technology. Once is not enough. Jama, 264(2), 235-240. 4. Bleibler, F., Rapp, K., Jaensch, A., Becker, C., König, H. H. (2014). Expected lifetime numbers and costs of fractures in postmenopausal women with and without osteoporosis in Germany: a discrete event simulation model. BMC Health Serv Res, 14, 284. doi:10.1186/1472-6963-14-284 5. Brozek, W., Reichardt, B., Zwerina, J., Dimai, H. P., Klaushofer, K., Zwettler, E. (2016). Antiresorptive therapy and risk of mortality and refracture in osteoporosis-related hip fracture: a nationwide study. Osteoporos Int, 27(1), 387-396. doi:10.1007/s00198-015-3415-4 6. Camacho, P. M., Petak, S. M., Binkley, N., Diab, D. L., Eldeiry, L. S., Farooki, A., . . . Watts, N. B. (2020). AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS/AMERICAN COLLEGE OF ENDOCRINOLOGY CLINICAL PRACTICE GUIDELINES FOR THE DIAGNOSIS AND TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS- 2020 UPDATE EXECUTIVE SUMMARY. Endocr Pract, 26(5), 564-570. doi:10.4158/gl-2020-0524 7. Center, J. R., Nguyen, T. V., Schneider, D., Sambrook, P. N., Eisman, J. A. (1999). Mortality after all major types of osteoporotic fracture in men and women: an observational study. Lancet, 353(9156), 878-882. doi:10.1016/s0140-6736(98)09075-8 8. Chan, D. C., Lee, Y. S., Wu, Y. J., Tsou, H. H., Chen, C. T., Hwang, J. S., . . . Yang, R. S. (2013). A 12-year ecological study of hip fracture rates among older Taiwanese adults. Calcif Tissue Int, 93(5), 397-404. doi:10.1007/s00223-013-9759-x 9. Chang, C. Y., Tang, C. H., Chen, K. C., Huang, K. C., Huang, K. C. (2016). The mortality and direct medical costs of osteoporotic fractures among postmenopausal women in Taiwan. Osteoporos Int, 27(2), 665-676. doi:10.1007/s00198-015-3238-3 10. Cooper, C. (1997). The crippling consequences of fractures and their impact on quality of life. Am J Med, 103(2a), 12S-17S; discussion 17S-19S. doi:10.1016/s0002-9343(97)90022-x 11. Cummings, S. R., Melton, L. J. (2002). Epidemiology and outcomes of osteoporotic fractures. Lancet, 359(9319), 1761-1767. doi:10.1016/s0140-6736(02)08657-9 12. Eisman, J., Clapham, S., Kehoe, L. (2004). Osteoporosis prevalence and levels of treatment in primary care: the Australian BoneCare Study. J Bone Miner Res, 19(12), 1969-1975. doi:10.1359/jbmr.040905 13. Fardellone, P., Cortet, B., Legrand, E., Bresse, X., Bisot-Locard, S., Vigneron, A. M., Beresniak, A. (2010). Cost-effectiveness model of using zoledronic acid once a year versus current treatment strategies in postmenopausal osteoporosis. Joint Bone Spine, 77(1), 53-57. doi:10.1016/j.jbspin.2009.04.009 14. Fatoye, F., Smith, P., Gebrye, T., Yeowell, G. (2019). Real-world persistence and adherence with oral bisphosphonates for osteoporosis: a systematic review. BMJ Open, 9(4), e027049. doi:10.1136/bmjopen-2018-027049 15. Gillespie, C. W., Morin, P. E. (2017). Osteoporosis-Related Health Services Utilization Following First Hip Fracture Among a Cohort of Privately-Insured Women in the United States, 2008-2014: An Observational Study. J Bone Miner Res, 32(5), 1052-1061. doi:10.1002/jbmr.3079 16. Hiligsmann, M., Boonen, A., Rabenda, V., Reginster, J. Y. (2012). The importance of integrating medication adherence into pharmacoeconomic analyses: the example of osteoporosis. Expert Rev Pharmacoecon Outcomes Res, 12(2), 159-166. doi:10.1586/erp.12.8 17. Hiligsmann, M., Cornelissen, D., Vrijens, B., Abrahamsen, B., Al-Daghri, N., Biver, E., . . . Reginster, J. Y. (2019). Determinants, consequences and potential solutions to poor adherence to anti-osteoporosis treatment: results of an expert group meeting organized by the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO) and the International Osteoporosis Foundation (IOF). Osteoporos Int, 30(11), 2155-2165. doi:10.1007/s00198-019-05104-5 18. Hui, S. L., Slemenda, C. W., Johnston, C. C., Jr. (1988). Age and bone mass as predictors of fracture in a prospective study. J Clin Invest, 81(6), 1804-1809. doi:10.1172/jci113523 19. Ito, K. (2018). Cost-effectiveness of single-dose zoledronic acid for nursing home residents with osteoporosis in the USA. BMJ Open, 8(9), e022585. doi:10.1136/bmjopen-2018-022585 20. Johnell, O., Kanis, J. A. (2006). An estimate of the worldwide prevalence and disability associated with osteoporotic fractures. Osteoporos Int, 17(12), 1726-1733. doi:10.1007/s00198-006-0172-4 21. Kanis, J. A. (2007). Assessment of osteoporosis at the primary health-care level. Retrieved from 22. Kanis, J. A., Cooper, C., Hiligsmann, M., Rabenda, V., Reginster, J. Y., Rizzoli, R. (2011). Partial adherence: a new perspective on health economic assessment in osteoporosis. Osteoporos Int, 22(10), 2565-2573. doi:10.1007/s00198-011-1668-0 23. Kanis, J. A., Johansson, H., Oden, A., Johnell, O., De Laet, C., Eisman, J. A., . . . Tenenhouse, A. (2004). A family history of fracture and fracture risk: a meta-analysis. Bone, 35(5), 1029-1037. doi:10.1016/j.bone.2004.06.017 24. Kanis, J. A., Johansson, H., Oden, A., Johnell, O., de Laet, C., Melton, I. L., . . . Mellstrom, D. (2004). A meta-analysis of prior corticosteroid use and fracture risk. J Bone Miner Res, 19(6), 893-899. doi:10.1359/jbmr.040134 25. Kanis, J. A., Johnell, O., De Laet, C., Johansson, H., Oden, A., Delmas, P., . . . Tenenhouse, A. (2004). A meta-analysis of previous fracture and subsequent fracture risk. Bone, 35(2), 375-382. doi:10.1016/j.bone.2004.03.024 26. Kanis, J. A., Oden, A., Johnell, O., Jonsson, B., de Laet, C., Dawson, A. (2001). The burden of osteoporotic fractures: a method for setting intervention thresholds. Osteoporos Int, 12(5), 417-427. doi:10.1007/s001980170112 27. Kim, T. Y., Jang, S., Park, C. M., Lee, A., Lee, Y. K., Kim, H. Y., . . . Ha, Y. C. (2016). Trends of Incidence, Mortality, and Future Projection of Spinal Fractures in Korea Using Nationwide Claims Data. J Korean Med Sci, 31(5), 801-805. doi:10.3346/jkms.2016.31.5.801 28. Klop, C., Gibson-Smith, D., Elders, P. J., Welsing, P. M., Leufkens, H. G., Harvey, N. C., . . . de Vries, F. (2015). Anti-osteoporosis drug prescribing after hip fracture in the UK: 2000-2010. Osteoporos Int, 26(7), 1919-1928. doi:10.1007/s00198-015-3098-x 29. Klotzbuecher, C. M., Ross, P. D., Landsman, P. B., Abbott, T. A., 3rd, Berger, M. (2000). Patients with prior fractures have an increased risk of future fractures: a summary of the literature and statistical synthesis. J Bone Miner Res, 15(4), 721-739. doi:10.1359/jbmr.2000.15.4.721 30. Lee, S. H., Chen, I. J., Li, Y. H., Fan Chiang, C. Y., Chang, C. H., Hsieh, P. H. (2016). Incidence of second hip fractures and associated mortality in Taiwan: A nationwide population-based study of 95,484 patients during 2006-2010. Acta Orthop Traumatol Turc, 50(4), 437-442. doi:10.1016/j.aott.2016.06.008 31. Leibson, C. L., Tosteson, A. N., Gabriel, S. E., Ransom, J. E., Melton, L. J. (2002). Mortality, disability, and nursing home use for persons with and without hip fracture: a population-based study. J Am Geriatr Soc, 50(10), 1644-1650. doi:10.1046/j.1532-5415.2002.50455.x 32. Lekkerkerker, F., Kanis, J. A., Alsayed, N., Bouvenot, G., Burlet, N., Cahall, D., . . . Reginster, J. Y. (2007). Adherence to treatment of osteoporosis: a need for study. Osteoporos Int, 18(10), 1311-1317. doi:10.1007/s00198-007-0410-4 33. Lips, P., Cooper, C., Agnusdei, D., Caulin, F., Egger, P., Johnell, O., . . . Wiklund, I. (1999). Quality of life in patients with vertebral fractures: validation of the Quality of Life Questionnaire of the European Foundation for Osteoporosis (QUALEFFO). Working Party for Quality of Life of the European Foundation for Osteoporosis. Osteoporos Int, 10(2), 150-160. doi:10.1007/s001980050210 34. MacKean, G., Noseworthy, T., Elshaug, A. G., Leggett, L., Littlejohns, P., Berezanski, J., Clement, F. (2013). Health technology reassessment: the art of the possible. Int J Technol Assess Health Care, 29(4), 418-423. doi:10.1017/s0266462313000494 35. McClung, M., Recker, R., Miller, P., Fiske, D., Minkoff, J., Kriegman, A., . . . Davis, J. (2007). Intravenous zoledronic acid 5 mg in the treatment of postmenopausal women with low bone density previously treated with alendronate. Bone, 41(1), 122-128. doi:10.1016/j.bone.2007.03.011 36. Melton, L. J., 3rd. (2000). Who has osteoporosis? A conflict between clinical and public health perspectives. J Bone Miner Res, 15(12), 2309-2314. doi:10.1359/jbmr.2000.15.12.2309 37. Meyer, H. E., Tverdal, A., Falch, J. A. (1995). BODY HEIGHT, BODY MASS INDEX, AND FATAL HIP FRACTURES: 16 YEARS' FOLLOW-UP OF 674,000 NORWEGIAN WOMEN AND MEN. Epidemiology, 6(3), 299-305. Retrieved from https://journals.lww.com/epidem/Fulltext/1995/05000/BODY_HEIGHT,_BODY_MASS_INDEX,_AND_FATAL_HIP.19.aspx 38. Mori, T., Crandall, C. J., Ganz, D. A. (2017). Cost-effectiveness of denosumab versus oral alendronate for elderly osteoporotic women in Japan. Osteoporos Int, 28(5), 1733-1744. doi:10.1007/s00198-017-3940-4 39. Moriwaki, K., Mouri, M., Hagino, H. (2017). Cost-effectiveness analysis of once-yearly injection of zoledronic acid for the treatment of osteoporosis in Japan. Osteoporos Int, 28(6), 1939-1950. doi:10.1007/s00198-017-3973-8 40. Rose, S. H., Melton, L. J., 3rd, Morrey, B. F., Ilstrup, D. M., Riggs, B. L. (1982). Epidemiologic features of humeral fractures. Clin Orthop Relat Res(168), 24-30. 41. Ross, P. D. (1996). Osteoporosis: Frequency, Consequences, and Risk Factors. Archives of Internal Medicine, 156(13), 1399-1411. doi:10.1001/archinte.1996.00440120051005 42. Roux, C., Wyman, A., Hooven, F. H., Gehlbach, S. H., Adachi, J. D., Chapurlat, R. D., . . . Boonen, S. (2012). Burden of non-hip, non-vertebral fractures on quality of life in postmenopausal women: the Global Longitudinal study of Osteoporosis in Women (GLOW). Osteoporos Int, 23(12), 2863-2871. doi:10.1007/s00198-012-1935-8 43. Shao, C. J., Hsieh, Y. H., Tsai, C. H., Lai, K. A. (2009). A nationwide seven-year trend of hip fractures in the elderly population of Taiwan. Bone, 44(1), 125-129. doi:10.1016/j.bone.2008.09.004 44. Shen, G. S., Li, Y., Zhao, G., Zhou, H. B., Xie, Z. G., Xu, W., . . . Xu, Y. J. (2015). Cigarette smoking and risk of hip fracture in women: a meta-analysis of prospective cohort studies. Injury, 46(7), 1333-1340. doi:10.1016/j.injury.2015.04.008 45. Shoback, D., Rosen, C. J., Black, D. M., Cheung, A. M., Murad, M. H., Eastell, R. (2020). Pharmacological Management of Osteoporosis in Postmenopausal Women: An Endocrine Society Guideline Update. J Clin Endocrinol Metab, 105(3). doi:10.1210/clinem/dgaa048 46. Si, L., Winzenberg, T. M., de Graaff, B., Palmer, A. J. (2014). A systematic review and meta-analysis of utility-based quality of life for osteoporosis-related conditions. Osteoporos Int, 25(8), 1987-1997. doi:10.1007/s00198-014-2636-2 47. Soong, Y. K., Tsai, K. S., Huang, H. Y., Yang, R. S., Chen, J. F., Wu, P. C., Huang, K. E. (2013). Risk of refracture associated with compliance and persistence with bisphosphonate therapy in Taiwan. Osteoporos Int, 24(2), 511-521. doi:10.1007/s00198-012-1984-z 48. Sun, S., Chen, J., Johannesson, M., Kind, P., Xu, L., Zhang, Y., Burström, K. (2011). Population health status in China: EQ-5D results, by age, sex and socio-economic status, from the National Health Services Survey 2008. Qual Life Res, 20(3), 309-320. doi:10.1007/s11136-010-9762-x 49. Wang, C. Y., Fu, S. H., Yang, R. S., Shen, L. J., Wu, F. L., Hsiao, F. Y. (2017). Age- and gender-specific epidemiology, treatment patterns, and economic burden of osteoporosis and associated fracture in Taiwan between 2009 and 2013. Arch Osteoporos, 12(1), 92. doi:10.1007/s11657-017-0385-5 50. Ward, K. D., Klesges, R. C. (2001). A meta-analysis of the effects of cigarette smoking on bone mineral density. Calcif Tissue Int, 68(5), 259-270. doi:10.1007/bf02390832 51. World Health Organization. (1993). Consensus development conference: diagnosis, prophylaxis, and treatment of osteoporosis. Retrieved from 52. World Health Organization. (1994). Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. Report of a WHO Study Group. Retrieved from 53. World Health Organization. (2021). HTA Definitions. Retrieved from https://www.who.int/health-technology-assessment/about/Defining/en/ 54. You, R., Zhang, Y., Wu, D. B., Liu, J., Qian, X., Luo, N., Mori, T. (2020). Cost-Effectiveness of Zoledronic Acid Versus Oral Alendronate for Postmenopausal Osteoporotic Women in China. Front Pharmacol, 11, 456. doi:10.3389/fphar.2020.00456 55. 中華民國骨質疏鬆症學會. (2020). 台灣成人骨質疏鬆症防治之共識及指引. 臺北市: 中華民國骨質疏鬆症學會. 56. 王貞予. (2019). 台灣骨質疏鬆症之流行病學、醫療經濟負擔、未滿足醫療需求以及適當起始治療時機. 國立臺灣大學, Available from Airiti AiritiLibrary database. (2019年) 57. 余傑明, 吳岱穎, 楊榮森, 廖振焜, 樓亞洲, 陳建志. (2012). 骨質疏鬆症的藥物治療. [Pharmacotherapy of Osteoporosis]. 台灣老年醫學暨老年學雜誌, 7(2), 77-90. doi:10.29461/tgg.201205.0002 58. 沈昀儒, 陳弘哲, 陳如意. (2020). 定量超音波（QUS）於骨質疏鬆症之應用. 家庭醫學與基層醫療, 35(10), 304-309. 59. 周輝政、楊東川. (2018). 更年期與骨質疏鬆. Retrieved from https://www.hpa.gov.tw/Pages/Detail.aspx?nodeid=634 pid=1197 60. 柯靜華. (2018). Real World Data介紹及於醫療科技評估之應用. 當代醫藥法規月刊, 97, 11-20. 61. 財團法人醫藥品查驗中心. (2013). 醫療科技評估成本效益分析方法學指引. Retrieved from https://www3.cde.org.tw/Content/Files/HTA/3/3_%E9%86%AB%E7%99%82%E7%A7%91%E6%8A%80%E8%A9%95%E4%BC%B0%E6%96%B9%E6%B3%95%E5%AD%B8%E6%8C%87%E5%BC%95CEA.pdf 62. 黃珮茹. (2012). 探討老人髖部骨折之相關危險因子 一個病歷對照研究. 中山醫學大學, Available from Airiti AiritiLibrary database. (2012年) 63. 楊南屏, 楊榮森, 周碧瑟. (2008). 提早因應高齡化社會的特殊醫療保健需求：以骨質疏鬆症為例. [Actions in Advance to the Special Medical Care Need in an Aging Society: Osteoporosis as an Example]. 台灣公共衛生雜誌, 27(3), 181-197. doi:10.6288/tjph2008-27-03-01 64. 葉慶輝, 葉淑娟. (2007). 台灣南部健檢成人骨質疏鬆症之盛行率與危險因子探討. [Prevalence and Risk Factors of Osteoporosis among Adults Undergoing Health Examinations in Southern Taiwan]. 台灣公共衛生雜誌, 26(6), 462-471. doi:10.6288/tjph2007-26-06-03 65. 賴美祁. (2019). 淺談醫療科技再評估. 當代醫藥法規月刊, 99, 21-38. Retrieved from https://www.cde.org.tw/Content/Files/Knowledge/55df2d3f-70ba-447f-8062-6e974478469e.pdf | |
| dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/80404 | - |
| dc.description.abstract | "研究背景 目前雙磷酸鹽類藥物最常被使用於預防以及治療骨質疏鬆症，此類藥物過去已被證實能提升骨質密度、降低骨折發生率，由於藥物實際使用情形會影響發生脆弱性骨折風險、品質調整壽命年高低以及骨折相關的治療成本，考量到藥物在現實社會中帶來的影響，本研究因此欲以真實世界數據分析對醫療體系實際成本與效用的影響。 研究目的 本研究以衛生福利部中央健康保險署觀點，比較使用Zoledronic acid 5mg相對於Alendronate 70 mg治療停經後骨質疏鬆症之成本效用，進行醫療科技再評估(health technology reassessment, HTR)研究以補足目前台灣研究之缺口，提供未來保險給付政策以及臨床治療參考。 研究方法 本研究對象為65歲以上停經後且患有骨質疏鬆症之婦女，介入藥品為一年注射一次的Zoledronic acid 5 mg，比較品為口服的Alendronate 70 mg，主要評估結果為醫療費用以及生活品質校正生命年(QALY)。評估方法為建構馬可夫模型模擬兩種治療之醫療成本以及效用，模擬週期為1年，評估期間為40年。骨折相關醫療費用之參數、骨折轉換機率、再骨折機率及治療骨折之醫療費用係透過分析2012年至2018年之全民健康保險研究資料庫兩百萬抽樣歸人檔，取得我國相關數據；各個健康狀態的效用值由文獻獲得。最後根據模擬結果計算遞增成本效果比值(Incremental cost-effectiveness ratio, ICER)，並針對重要參數進行決定性敏感度分析以及機率性敏感度分析。 研究結果 病患使用Zoledronic acid 5 mg以及Alendronate 70 mg治療骨質疏鬆症四十年獲得的效用分別為10.87以及10.66生活品質校正生命年(QALY)，平均每人四十年治療成本為新台幣428,369.85元以及427,935.5元，ICER為$1,902.45/QALY，Zoledronic acid 5 mg相較於Alendronate 70 mg具有成本效果。使用Zoledronic acid 5 mg治療骨質疏鬆症患者具有成本效果的機率，閾值為一倍(新臺幣839,558元)及三倍(新臺幣2,518,674元)的2020年之人均國內生產毛額時分別為96.3%及99.7%。 研究結論 相較於Alendronate 70 mg相比，使用Zoledronic acid 5mg治療骨質疏鬆症為具有成本效果的治療選擇。" | zh_TW |
| dc.description.provenance | Made available in DSpace on 2022-11-24T03:05:55Z (GMT). No. of bitstreams: 1 U0001-1101202216014500.pdf: 1996440 bytes, checksum: 826b4dca4562a3b64fe5e31a9aa66232 (MD5) Previous issue date: 2022 | en |
| dc.description.tableofcontents | 致謝 i 中文摘要 ii Abstract iv 目 錄 vi 第一章 緒論 1 第一節 研究背景 1 第二節 研究動機與重要性 2 第三節 研究目的 3 第二章 文獻回顧 4 第一節 骨質疏鬆症概述與現況 4 第二節 骨質疏鬆症之流行病學 7 第三節 現行治療方式 12 第四節 經濟評估方法 14 第五節 相關經濟評估實證研究 16 第六節 文獻小結 19 第三章 研究方法與材料 20 第一節 研究設計 20 第二節 資料來源與醫療服務利用 23 第三節 模型參數來源及定義 34 第四節 研究假設 38 第五節 分析工具及方法 39 第四章 研究結果 45 第一節 研究對象基本特質 45 第二節 成本效果分析結果 48 第三節 單維敏感度分析(one way sensitivity analysis) 50 第四節 情境分析(scenario analysis) 51 第五節 機率敏感度分析(probabilistic sensitivity analysis) 54 第五章 討論 56 第一節 真實世界資料分析結果 56 第二節 主要研究發現 58 第三節 研究限制 60 第六章 結論與建議 62 第一節 結論 62 第二節 建議 63 參考文獻 64 附錄 72 | |
| dc.language.iso | zh-TW | |
| dc.subject | Alendronate 70 mg | zh_TW |
| dc.subject | 成本效用分析 | zh_TW |
| dc.subject | Zoledronic acid 5mg | zh_TW |
| dc.subject | 骨質疏鬆症 | zh_TW |
| dc.subject | zoledronic acid | en |
| dc.subject | alendronate | en |
| dc.subject | cost-utility analysis | en |
| dc.subject | osteoporosis | en |
| dc.title | 停經後婦女使用Zoledronic acid 5 mg相對於Alendronate 70 mg治療骨質疏鬆症之成本效用分析 | zh_TW |
| dc.title | Cost-Utility Analysis of Zoledronic Acid 5 mg Compare with Alendronate 70 mg for the treatment of postmenopausal osteoporosis patients in Taiwan | en |
| dc.date.schoolyear | 110-1 | |
| dc.description.degree | 碩士 | |
| dc.contributor.oralexamcommittee | 蕭斐元(Chii-Shen Yang),譚家惠(Hsiao-Chun Huang) | |
| dc.subject.keyword | 骨質疏鬆症,成本效用分析,Zoledronic acid 5mg,Alendronate 70 mg, | zh_TW |
| dc.subject.keyword | osteoporosis,cost-utility analysis,zoledronic acid,alendronate, | en |
| dc.relation.page | 73 | |
| dc.identifier.doi | 10.6342/NTU202200041 | |
| dc.rights.note | 同意授權(限校園內公開) | |
| dc.date.accepted | 2022-01-12 | |
| dc.contributor.author-college | 公共衛生學院 | zh_TW |
| dc.contributor.author-dept | 健康政策與管理研究所 | zh_TW |
| 顯示於系所單位： | 健康政策與管理研究所 | |
文件中的檔案：
| 檔案 | 大小 | 格式 | |
|---|---|---|---|
| U0001-1101202216014500.pdf 授權僅限NTU校內IP使用（校園外請利用VPN校外連線服務） | 1.95 MB | Adobe PDF |
系統中的文件，除了特別指名其著作權條款之外，均受到著作權保護，並且保留所有的權利。